organization · Reporting owner
Tactic Pharma LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Monopar Therapeutics
Report date September 24, 2025 · Filed September 26, 2025
Jointly reported with Robinson Chandler, Brown Michael J, O'Halloran Thomas V., Mazar Andrew Paul
Section 16 reporting ended · disclosed 2025-09-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 272,026 |
Reported balance
After 2025-09-24 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-09-24 · Sale · Disposed 550,229 · Balance 272,026 F1: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. The Reporting Persons are no longer subject to Section 16, except for Chandler D. Robinson, who serves as Chief Executive Officer of Monopar Therapeutics Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. The Reporting Persons are no longer subject to Section 16, except for Chandler D. Robinson, who serves as Chief Executive Officer of Monopar Therapeutics Inc.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 24, 2025 Filed Sep 26, 2025 15:53 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 550,229 | $63.61 | $34,999,956.64 |
DisclosureSEC source: 0001437749-25-029925 · rdgdoc.xml · nonDerivative · entry 1 Tactic Pharma LLC · CIK 0001727357 · 10% owner Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer Brown Michael J · CIK 0001035909 · Member of 10% Owner Group O'Halloran Thomas V. · CIK 0001727481 · Member of 10% Owner Group Mazar Andrew Paul · CIK 0001727393 · Member of 10% Owner Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 272,026 F1 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. The Reporting Persons are no longer subject to Section 16, except for Chandler D. Robinson, who serves as Chief Executive Officer of Monopar Therapeutics Inc. Read SEC document |
| April 02, 2025 Filed Apr 4, 2025 19:27 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 33,334 | $35.00 | $1,166,690.00 |
DisclosureSEC source: 0001437749-25-011068 · rdgdoc.xml · nonDerivative · entry 1 Tactic Pharma LLC · CIK 0001727357 · 10% owner Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer Brown Michael J · CIK 0001035909 · Member of 10% Owner Group O'Halloran Thomas V. · CIK 0001727481 · Member of 10% Owner Group Mazar Andrew Paul · CIK 0001727393 · Member of 10% Owner Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 822,255 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.86, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 19:35 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon stock | 11,929 | $16.90 | $201,600.10 |
DisclosureSEC source: 0001654954-21-001750 · section16.xml · nonDerivative · entry 5 Tactic Pharma LLC · CIK 0001727357 · 10% owner Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer O'Halloran Thomas V. · CIK 0001727481 · 10% owner Brown Michael J · CIK 0001035909 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,667 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 24, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.77 to $17.01, inclusive. F2 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 19:35 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon stock | 16,384 | $16.44 | $269,352.96 |
DisclosureSEC source: 0001654954-21-001750 · section16.xml · nonDerivative · entry 4 Tactic Pharma LLC · CIK 0001727357 · 10% owner Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer O'Halloran Thomas V. · CIK 0001727481 · 10% owner Brown Michael J · CIK 0001035909 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,596 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 24, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.77 to $16.76, inclusive. F2 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 19:35 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon stock | 29,996 | $15.12 | $453,539.52 |
DisclosureSEC source: 0001654954-21-001750 · section16.xml · nonDerivative · entry 3 Tactic Pharma LLC · CIK 0001727357 · 10% owner Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer O'Halloran Thomas V. · CIK 0001727481 · 10% owner Brown Michael J · CIK 0001035909 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,980 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 24, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.76 to $15.75, inclusive. F2 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 19:35 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon stock | 24,224 | $14.09 | $341,316.16 |
DisclosureSEC source: 0001654954-21-001750 · section16.xml · nonDerivative · entry 2 Tactic Pharma LLC · CIK 0001727357 · 10% owner Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer O'Halloran Thomas V. · CIK 0001727481 · 10% owner Brown Michael J · CIK 0001035909 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,976 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 24, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.66 to $14.54, inclusive. F2 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 19:35 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon stock | 42,467 | $13.30 | $564,811.10 |
DisclosureSEC source: 0001654954-21-001750 · section16.xml · nonDerivative · entry 1 Tactic Pharma LLC · CIK 0001727357 · 10% owner Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer O'Halloran Thomas V. · CIK 0001727481 · 10% owner Brown Michael J · CIK 0001035909 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,200 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 24, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.66 to $13.65, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (7) to this Form 4. F2 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 18:33 UTC | Monopar Therapeutics MNPR · Entity 5152 | PurchaseCommon stock | 125,000 | $8.00 | $1,000,000.00 |
DisclosureSEC source: 0001654954-19-014150 · section16.xml · nonDerivative · entry 1 Tactic Pharma LLC · CIK 0001727357 · 10% owner Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer · 10% owner Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer · 10% owner O'Halloran Thomas V. · CIK 0001727481 · 10% owner Brown Michael J · CIK 0001035909 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,667 F1 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.